IN2014DE00554A - - Google Patents

Download PDF

Info

Publication number
IN2014DE00554A
IN2014DE00554A IN554DE2014A IN2014DE00554A IN 2014DE00554 A IN2014DE00554 A IN 2014DE00554A IN 554DE2014 A IN554DE2014 A IN 554DE2014A IN 2014DE00554 A IN2014DE00554 A IN 2014DE00554A
Authority
IN
India
Prior art keywords
relates
present
phoshpoinositide
pi3k
anticancer
Prior art date
Application number
Inventor
Ram Asrey Vishwakarma
Sandip Bibishan Bharate
Shashi Bhushan
Rammohan Rao Yadav
Santosh Kumar Guru
Prashant Joshi
Original Assignee
Csir
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Csir filed Critical Csir
Priority to PCT/IN2015/000088 priority Critical patent/WO2015128873A1/en
Priority to IN554DE2014 priority patent/IN2014DE00554A/en
Priority to US15/121,328 priority patent/US10202374B2/en
Priority to EP15720483.5A priority patent/EP3110801B1/en
Priority to CA2940412A priority patent/CA2940412C/en
Publication of IN2014DE00554A publication Critical patent/IN2014DE00554A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
    • C07D239/94—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond

Abstract

The present invention relates to 6-aryl-4-phenylamino quinazolines of formula I wherein, R and R' are as herein described. The present invention particularly relates to synthesis and anticancer and phoshpoinositide-3-kinase-a (PI3K-a) inhibitory activity. In addition, the invention relates to methods of using compounds for treating or preventing various cancers such as pancreatic, prostate, breast and melanoma.
IN554DE2014 2014-02-27 2015-02-16 IN2014DE00554A (en)

Priority Applications (5)

Application Number Priority Date Filing Date Title
PCT/IN2015/000088 WO2015128873A1 (en) 2014-02-27 2015-02-16 "6-aryl-4-phenylamino-quinazoline analogs as phosphoinositide-3-kinase inhibitors"
IN554DE2014 IN2014DE00554A (en) 2014-02-27 2015-02-16
US15/121,328 US10202374B2 (en) 2014-02-27 2015-02-16 6-aryl-4-phenylamino-quinazoline analogs as phosphoinositide-3-kinase inhibitors
EP15720483.5A EP3110801B1 (en) 2014-02-27 2015-02-16 6-aryl-4-phenylamino-quinazoline analogs as phosphoinositide-3-kinase inhibitors
CA2940412A CA2940412C (en) 2014-02-27 2015-02-16 6-aryl-4-phenylamino-quinazoline analogs as phosphoinositide-3-kinase inhibitors

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IN554DE2014 IN2014DE00554A (en) 2014-02-27 2015-02-16

Publications (1)

Publication Number Publication Date
IN2014DE00554A true IN2014DE00554A (en) 2015-08-28

Family

ID=53051870

Family Applications (1)

Application Number Title Priority Date Filing Date
IN554DE2014 IN2014DE00554A (en) 2014-02-27 2015-02-16

Country Status (5)

Country Link
US (1) US10202374B2 (en)
EP (1) EP3110801B1 (en)
CA (1) CA2940412C (en)
IN (1) IN2014DE00554A (en)
WO (1) WO2015128873A1 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105237484B (en) * 2015-09-28 2018-12-07 西安交通大学 The quinolines and its application that a kind of 6- aryl replaces

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9424233D0 (en) * 1994-11-30 1995-01-18 Zeneca Ltd Quinazoline derivatives
GB9603095D0 (en) * 1996-02-14 1996-04-10 Zeneca Ltd Quinazoline derivatives
WO2008009078A2 (en) 2006-07-20 2008-01-24 Gilead Sciences, Inc. 4,6-dl- and 2,4,6-trisubstituted quinazoline derivatives useful for treating viral infections
UY31137A1 (en) 2007-06-14 2009-01-05 Smithkline Beecham Corp DERIVATIVES OF QUINAZOLINE AS INHIBITORS OF THE PI3 QUINASA
JP5819831B2 (en) * 2009-08-17 2015-11-24 インテリカイン， エルエルシー Heterocyclic compounds and their use
EP2776837A4 (en) * 2011-11-11 2015-05-20 Intellikine Llc Combination of kinase inhibitors and uses thereof

Also Published As

Publication number Publication date
CA2940412A1 (en) 2015-09-03
CA2940412C (en) 2022-07-12
EP3110801B1 (en) 2019-01-30
WO2015128873A4 (en) 2016-01-28
WO2015128873A9 (en) 2015-12-03
EP3110801A1 (en) 2017-01-04
WO2015128873A1 (en) 2015-09-03
US20170015662A1 (en) 2017-01-19
US10202374B2 (en) 2019-02-12

Similar Documents

Publication Publication Date Title
MX2023005804A (en) Pyridazinones as parp7 inhibitors.
MX2020013649A (en) Compositions and methods for inhibiting arginase activity.
PH12018500899A1 (en) Compositions and methods for inhibiting arginase activity
MX2020010496A (en) Inhibitors of lysine specific demethylase-1.
MX2017002824A (en) Inhibitors of lysine specific demethylase-1.
PH12018502535A1 (en) Substituted carbonucleoside derivatives useful as anticancer agents
MX2017000179A (en) Inhibitors of lysine specific demethylase-1.
MX2017000168A (en) Inhibitors of lysine specific demethylase-1.
MX2017000170A (en) Inhibitors of lysine specific demethylase-1.
TW201613882A (en) Histone demethylase inhibitors
ECSP17020172A (en) HISTONE DESMETILASE INHIBITORS
MX2019013808A (en) Compounds for treatment of cancer.
PH12019502363A1 (en) Phenyl-2-hydroxy-acetylamino-2-methyl-phenyl compounds
UA114417C2 (en) Inhibitors of iap
MX2013002155A (en) Compounds for treatment of cancer.
WO2019023315A3 (en) Rac inhibitors
EA201790604A1 (en) Inhibitors of histonedehylase
IN2014DE00554A (en)
PH12017501147A1 (en) Total synthesis of trioxacarcin dc-45-a2 and preparation of trioxacarcin analogs
WO2015057737A3 (en) COMPOSITIONS AND METHODS FOR THE TREATMENT OF VprBP-RELATED CANCERS
IN2013DE03665A (en)
GB2553684A8 (en) Ethynylxanthines, preparation and use for cancer treatment